nach oben

Erschienen in:

01.04.2009 | Laboratory Investigation - Human/Animal Tissue

Growth factor receptors signaling in glioblastoma cells: therapeutic implications

verfasst von: Mia Carapancea, Oana Alexandru, Ani S. Fetea, Laura Dragutescu, Juan Castro, Ada Georgescu, A. Popa-Wagner, Magnus L. Bäcklund, Rolf Lewensohn, Anica Dricu

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

In this study, we investigated the protein expression of platelet-derived growth factor receptor (PDGFR), insulin like growth factor-1 receptor (IGF-1R), phosphatidylinositol 3-kinase (PI3-K) and extracellular signal-regulated kinase (ERK1/2) in five primary glioblastoma (GB), with a view to their possible use as therapeutic targets. Our results demonstrated that appreciable levels of these proteins could be detected in the analysed GB cell lines, except for a low level of PDGFR and ERK1/2 expression in one GB cell line. The small molecule inhibitors towards IGF-1R, PDGFR, PI3-K and ERK1/2 respectively, have only modest or no anti-tumour activity on GB cells and therefore their combination with other therapy modalities was analysed. The interaction between small inhibitors and radiation was mostly additive or sub-additive; synergistic interaction was found in five of forty analysed combinations. Our results showed that GB cells are in general resistant to treatment and illustrate the difficulties in predicting the treatment response in malignant gliomas.

Allalunis-Turner MJ, Zia PK, Barron GM, Mirzayans R, Day RSIII (1995) Radiation-induced DNA damage and repair in cells of a radiosensitive human malignant glioma cell line. Radiat Res 144:288–293. doi:10.2307/3578948 PubMedCrossRef

Anderson CW, Dunn JJ, Freimuth PI, Galloway AM, Allalunis-Turner MJ (2001) Frameshift mutation in PRKDC, the gene for DNA-PKcs, in the DNA repair-defective, human, glioma-derived cell line M059J. Radiat Res 156:2–9. doi:10.1667/0033-7587(2001)156[0002:FMIPTG]2.0.CO;2 PubMedCrossRef

Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, Baserga R, Iliakis G, Aiken RD (2001) Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19:2189–2200PubMed

Antoniades HN, Galanopoulos T, Neville-Golden J, Maxwell M (1992) Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer 50:215–222. doi:10.1002/ijc.2910500210 PubMedCrossRef

Backlund LM, Nilsson BR, Goike HM, Schmidt EE, Liu L, Ichimura K, Collins VP (2003) Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res 9:4151–4158PubMed

Backlund LM, Nilsson BR, Liu L, Ichimura K, Collins VP (2005) Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas. Br J Cancer 93:124–130. doi:10.1038/sj.bjc.6602661 PubMedCrossRef

Baserga R, Sell C, Porcu P, Rubini M (1994) The role of the IGF-I receptor in the growth and transformation of mammalian cells. Cell Prolif 27:63–71. doi:10.1111/j.1365-2184.1994.tb01406.x PubMedCrossRef

Bridle KR, Li L, O’Neill R, Britton RS, Bacon BR (2006) Coordinate activation of intracellular signaling pathways by insulin-like growth factor-1 and platelet-derived growth factor in rat hepatic stellate cells. J Lab Clin Med 147:234–241. doi:10.1016/j.lab.2005.12.009 PubMedCrossRef

Brodt P, Samani A, Navab R (2000) Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol 60:1101–1107. doi:10.1016/S0006-2952(00)00422-6 PubMedCrossRef

10.

Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655–1657. doi:10.1126/science.296.5573.1655 PubMedCrossRef

11.

Chakravarti A, Loeffler JS, Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62:200–207PubMed

12.

Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55. doi:10.1016/0065-2571(84)90007-4 PubMedCrossRef

13.

Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R, Dricu A (2007) Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 26:2423–2434. doi:10.1038/sj.onc.1210037 PubMedCrossRef

14.

Del Valle L, Enam S, Lassak A, Wang JY, Croul S, Khalili K, Reiss K (2002) Insulin-like growth factor I receptor activity in human medulloblastomas. Clin Cancer Res 8:1822–1830PubMed

15.

DiBiase SJ, Zeng ZC, Chen R, Hyslop T, Curran WJ Jr, Iliakis G (2000) DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Cancer Res 60:1245–1253PubMed

16.

Dimova EY, Moller U, Herzig S, Fink T, Zachar V, Ebbesen P, Kietzmann T (2005) Transcriptional regulation of plasminogen activator inhibitor-1 expression by insulin-like growth factor-1 via MAP kinases and hypoxia-inducible factor-1 in HepG2 cells. Thromb Haemost 93:1176–1184PubMed

17.

Dricu A, Carlberg M, Wang M, Larsson O (1997) Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: role of down-regulation of the insulin-like growth factor 1 receptor in induction of apoptosis. Cancer Res 57:543–548PubMed

18.

Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU (1992) Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52:4550–4553PubMed

19.

Fomchenko EI, Holland EC (2007) Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment. Neurosurg Clin N Am 18:39–58, viii. doi:10.1016/j.nec.2006.10.006

20.

Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, Church D, Hassan AB (2005) Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 205:145–153. doi:10.1002/path.1712 PubMedCrossRef

21.

Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30:193–204. doi:10.1016/j.ctrv.2003.07.007 PubMedCrossRef

22.

Froesch ER, Schmid C, Schwander J, Zapf J (1985) Actions of insulin-like growth factors. Annu Rev Physiol 47:443–467. doi:10.1146/annurev.ph.47.030185.002303 PubMedCrossRef

23.

Germano IM, Ito M, Cho KG, Hoshino T, Davis RL, Wilson CB (1989) Correlation of histopathological features and proliferative potential of gliomas. J Neurosurg 70:701–706PubMed

24.

Grossman SA, Batara JF (2004) Current management of glioblastoma multiforme. Semin Oncol 31:635–644. doi:10.1053/j.seminoncol.2004.07.005 PubMedCrossRef

25.

Hagerstrand D, Hesselager G, Achterberg S, Wickenberg Bolin U, Kowanetz M, Kastemar M, Heldin CH, Isaksson A, Nister M, Ostman A (2006) Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 25:4913–4922. doi:10.1038/sj.onc.1209497 PubMedCrossRef

26.

Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR (2006) Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 32:74–89. doi:10.1016/j.ctrv.2006.01.003 PubMedCrossRef

27.

Han VK, D’Ercole AJ, Lund PK (1987) Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. Science 236:193–197. doi:10.1126/science.3563497 PubMedCrossRef

28.

Hanada M, Feng J, Hemmings BA (2004) Structure, regulation and function of PKB/AKT—a major therapeutic target. Biochim Biophys Acta 1697:3–16PubMed

29.

Hoppe BS, Jensen RB, Kirchgessner CU (2000) Complementation of the radiosensitive M059J cell line. Radiat Res 153:125–130. doi:10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2 PubMedCrossRef

30.

Jiang R, Mircean C, Shmulevich I, Cogdell D, Jia Y, Tabus I, Aldape K, Sawaya R, Bruner JM, Fuller GN, Zhang W (2006) Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics 6:2964–2971. doi:10.1002/pmic.200500555 PubMedCrossRef

31.

Johnson TR, Trojan J, Anthony DD, Rudin SD, Tykocinski ML, Ilan J, Ilan J (1994) Gene therapy of rat brain glioblastoma by an episome-based transcriptional cassette expressing antisense IGF-I cDNA. Indian J Biochem Biophys 31:1–13PubMedCrossRef

32.

Kasprzak HA, Trojan J, Bierwagen M, Kopinski P, Jarocki P, Bartczak K, Czapiewska J (2006) [Usefulness of the antisense and triplex anti-IGF-1 techniques for postoperative cellular gene therapy of malignant gliomas expressing IGF-1]. Neurol Neurochir Pol 40:509–515 (discussion 516)

33.

Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215–244. doi:10.1210/er.21.3.215 PubMedCrossRef

34.

Kiess W, Lee L, Graham DE, Greenstein L, Tseng LY, Rechler MM, Nissley SP (1989) Rat C6 glial cells synthesize insulin-like growth factor I (IGF-I) and express IGF-I receptors and IGF-II/mannose 6-phosphate receptors. Endocrinology 124:1727–1736PubMedCrossRef

35.

Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O’Reilly T, Buchdunger E, Black PM, Stiles CD (2000) Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60:5143–5150PubMed

36.

Kurmasheva RT, Houghton PJ (2006) IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 1766:1–22PubMed

37.

Lees-Miller SP, Godbout R, Chan DW, Weinfeld M, Day RSIII, Barron GM, Allalunis-Turner J (1995) Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line. Science 267:1183–1185. doi:10.1126/science.7855602 PubMedCrossRef

38.

Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA (2002) Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62:3729–3735PubMed

39.

Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275–292. doi:10.1002/path.1706 PubMedCrossRef

40.

Ly A, Duc HT, Kalamarides M, Trojan LA, Pan Y, Shevelev A, Francois JC, Noel T, Kane A, Henin D, Anthony DD, Trojan J (2001) Human glioma cells transformed by IGF-I triple helix technology show immune and apoptotic characteristics determining cell selection for gene therapy of glioblastoma. Mol Pathol 54:230–239. doi:10.1136/mp.54.4.230 PubMedCrossRef

41.

MacKeigan JP, Taxman DJ, Hunter D, Earp HSIII, Graves LM, Ting JP (2002) Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase inhibition. Clin Cancer Res 8:2091–2099PubMed

42.

Martin DM, Yee D, Carlson RO, Feldman EL (1992) Gene expression of the insulin-like growth factors and their receptors in human neuroblastoma cell lines. Brain Res Mol Brain Res 15:241–246. doi:10.1016/0169-328X(92)90114-Q PubMedCrossRef

43.

Mauro A, Di Sapio A, Mocellini C, Schiffer D (1995) Control of meningioma cell growth by platelet-derived growth factor (PDGF). J Neurol Sci 131:135–143. doi:10.1016/0022-510X(95)00106-C PubMedCrossRef

44.

Mrugala MM, Kesari S, Ramakrishna N, Wen PY (2004) Therapy for recurrent malignant glioma in adults. Expert Rev Anticancer Ther 4:759–782. doi:10.1586/14737140.4.5.759 PubMedCrossRef

45.

Nathoo N, Goldlust S, Vogelbaum MA (2004) Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas. Neurosurgery 54:1480–1488. doi:10.1227/01.NEU.0000125006.88478.F6 (discussion 1488–1489)PubMedCrossRef

46.

Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R (2006) Epidermal growth factor receptor—mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12:7261–7270. doi:10.1158/1078-0432.CCR-06-0874 PubMedCrossRef

47.

Nicholson KM, Anderson NG (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14:381–395. doi:10.1016/S0898-6568(01)00271-6 PubMedCrossRef

48.

Ozaki K (2007) Targeted molecular strategies for cancer therapy based on the blockade of oncogenic pathways in human tumor cells. Yakugaku Zasshi 127:983–991. doi:10.1248/yakushi.127.983 PubMedCrossRef

49.

Perer ES, Madan AK, Shurin A, Zakris E, Romeguera K, Pang Y, Beech DJ (2000) Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. J Surg Res 94:1–5. doi:10.1006/jsre.2000.5923 PubMedCrossRef

50.

Ponten J, Westermark B (1978) Properties of human malignant glioma cells in vitro. Med Biol 56:184–193PubMed

51.

Pulkkanen KJ, Yla-Herttuala S (2005) Gene therapy for malignant glioma: current clinical status. Mol Ther 12:585–598. doi:10.1016/j.ymthe.2005.07.357 PubMedCrossRef

52.

Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R (1994) Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54:2218–2222PubMed

53.

Resnicoff M, Li W, Basak S, Herlyn D, Baserga R, Rubin R (1996) Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA. Cancer Immunol Immunother 42:64–68. doi:10.1007/s002620050252 PubMedCrossRef

54.

Sandberg-Nordqvist AC, Stahlbom PA, Reinecke M, Collins VP, von Holst H, Sara V (1993) Characterization of insulin-like growth factor 1 in human primary brain tumors. Cancer Res 53:2475–2478PubMed

55.

Sanson M, Laigle-Donadey F, Benouaich-Amiel A (2006) Molecular changes in brain tumors: prognostic and therapeutic impact. Curr Opin Oncol 18:623–630. doi:10.1097/01.cco.0000245322.11787.72 PubMedCrossRef

56.

Schmidberger H, Rave-Frank M, Lehmann JJ, Weiss E, Gerl L, Dettmer N, Glomme S, Hess CF (2003) Lack of interferon beta-induced radiosensitization in four out of five human glioblastoma cell lines. Int J Radiat Oncol Biol Phys 55:1348–1357. doi:10.1016/S0360-3016(02)04575-3 PubMed

57.

Shamah SM, Stiles CD, Guha A (1993) Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol 13:7203–7212PubMed

58.

Soroceanu L, Kharbanda S, Chen R, Soriano RH, Aldape K, Misra A, Zha J, Forrest WF, Nigro JM, Modrusan Z, Feuerstein BG, Phillips HS (2007) Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci USA 104:3466–3471. doi:10.1073/pnas.0611271104 PubMedCrossRef

59.

Sourbier C, Lindner V, Lang H, Agouni A, Schordan E, Danilin S, Rothhut S, Jacqmin D, Helwig JJ, Massfelder T (2006) The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res 66:5130–5142. doi:10.1158/0008-5472.CAN-05-1469 PubMedCrossRef

60.

Strawn LM, Mann E, Elliger SS, Chu LM, Germain LL, Niederfellner G, Ullrich A, Shawver LK (1994) Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor. J Biol Chem 269:21215–21222PubMed

61.

Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial I, Anderson KC (2007) Targeting MEK induces myeloma cell cytotoxicity and inhibits osteoclastogenesis. Blood 110(5):1656–1663

62.

Trojan J, Blossey BK, Johnson TR, Rudin SD, Tykocinski M, Ilan J, Ilan J (1992) Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci USA 89:4874–4878. doi:10.1073/pnas.89.11.4874 PubMedCrossRef

63.

Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J (1993) Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259:94–97. doi:10.1126/science.8418502 PubMedCrossRef

64.

Trojan J, Duc HT, Upegui-Gonzalez LC, Hor F, Guo Y, Anthony D, Ilan J (1996) Presence of MHC-I and B-7 molecules in rat and human glioma cells expressing antisense IGF-I mRNA. Neurosci Lett 212:9–12. doi:10.1016/0304-3940(96)12770-1 PubMedCrossRef

65.

Trojan LA, Kopinski P, Wei MX, Ly A, Glogowska A, Czarny J, Shevelev A, Przewlocki R, Henin D, Trojan J (2002) IGF-I: from diagnostic to triple-helix gene therapy of solid tumors. Acta Biochim Pol 49:979–990PubMed

66.

Trojan LA, Kopinski P, Mazurek A, Chyczewski L, Ly A, Jarocki P, Niklinski J, Shevelev A, Trzos R, Pan Y, Gitis DJ, Bierwagen M, Czapiewska JL, Wei MX, Michalkiewicz J, Henin D, Popiela T, Evrard F, Kasprzak H, Anthony D, Trojan J (2003) IGF-I triple helix gene therapy of rat and human gliomas. Rocz Akad Med Bialymst 48:18–27PubMed

67.

Trojan J, Cloix JF, Ardourel MY, Chatel M, Anthony DD (2007) Insulin-like growth factor type I biology and targeting in malignant gliomas. Neuroscience 145:795–811. doi:10.1016/j.neuroscience.2007.01.021 PubMedCrossRef

68.

Vassbotn FS, Andersson M, Westermark B, Heldin CH, Ostman A (1993) Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant. Mol Cell Biol 13:4066–4076PubMed

69.

von Deimling A, Louis DN, Wiestler OD (1995) Molecular pathways in the formation of gliomas. Glia 15:328–338. doi:10.1002/glia.440150312 CrossRef

70.

Wen B, Deutsch E, Marangoni E, Frascona V, Maggiorella L, Abdulkarim B, Chavaudra N, Bourhis J (2001) Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 85:2017–2021. doi:10.1054/bjoc.2001.2171 PubMedCrossRef

71.

Wong ML, Kaye AH, Hovens CM (2007) Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci 14:301–308. doi:10.1016/j.jocn.2006.11.005 PubMedCrossRef

72.

Wu CJ, Chen Z, Ullrich A, Greene MI, O’Rourke DM (2000) Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs). Oncogene 19:3999–4010. doi:10.1038/sj.onc.1203748 PubMedCrossRef

73.

Yin D, Tamaki N, Parent AD, Zhang JH (2005) Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity. Neurol Res 27:27–35. doi:10.1179/016164105X18151 PubMedCrossRef

Titel: Growth factor receptors signaling in glioblastoma cells: therapeutic implications
verfasst von: Mia Carapancea
Oana Alexandru
Ani S. Fetea
Laura Dragutescu
Juan Castro
Ada Georgescu
A. Popa-Wagner
Magnus L. Bäcklund
Rolf Lewensohn
Anica Dricu
Publikationsdatum: 01.04.2009
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2009
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-008-9753-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Extremely late development of pituitary carcinoma after surgery and radiotherapy

Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival

Meningioma in untreated congenital adrenal hyperplasia: a relationship?

Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results

Rapid growth of primary cerebral fibrosarcoma with conversion to glioblastoma at second recurrence